Schnurr Max, Duewell Peter, Bauer Christian, Rothenfusser Simon, Lauber Kirsten, Endres Stefan, Kobold Sebastian
Division of Clinical Pharmacology & Center for Integrated Protein Science Munich (CIPSM), Klinikum der Universität München, Munich, Germany.
Immunotherapy. 2015;7(4):363-76. doi: 10.2217/imt.15.9.
Despite continuous progress in the understanding of deregulated pathways in pancreatic cancer cells and development of targeted therapies, therapeutic advances with clinical benefit have been scarce over the last decades. The recent success of immunotherapy for some solid cancers has fueled optimism that this approach might also work for pancreatic cancer. However, a highly immunosuppressive microenvironment mediated by tumor, stromal and immune cells creates a major hurdle for immunotherapy. Mouse models have helped to unravel critical immunosuppressive mechanisms that could serve as novel therapeutic targets. Here we review new promising strategies that alone or in combination with other modalities, such as chemotherapy or irradiation, have the potential to lead to tumor immune control and finally better clinical outcome.
尽管在理解胰腺癌细胞中失调的信号通路以及开发靶向治疗方面不断取得进展，但在过去几十年中，具有临床益处的治疗进展却很少。免疫疗法最近在一些实体癌治疗上取得的成功，激发了人们对于该方法也可能对胰腺癌有效的乐观情绪。然而，由肿瘤、基质和免疫细胞介导的高度免疫抑制微环境为免疫疗法带来了重大障碍。小鼠模型有助于揭示关键的免疫抑制机制，这些机制可作为新的治疗靶点。在这里，我们综述了一些新的有前景的策略，这些策略单独或与其他方式（如化疗或放疗）联合使用，有可能实现肿瘤免疫控制并最终带来更好的临床结果。
